Stuart Hwang

Stuart Hwang is an Inmedix investor and corporate development professional with more than 20 years in drug and diagnostic development. He has had extensive experience in developing strategic partnerships and fundraising with a cumulative transaction value greater than $2B. Prior to Inmedix, he has had an active advisory practice as a consultant and in investment banking supporting emerging and established biotech companies develop and execute on corporate strategy and transactions including partnerships, licensing, fundraising and M&A. Earlier, he led business development at Astex (acquired by Otuska).

Prior to that he held business development leadership roles at Perlegen and Agilent. He has led drug and diagnostic R&D teams at SuperGen, Cor Therapeutics, Millennium, Celera, Agilent and at UCSF/LBNL supporting 7 NME INDs and the development of 3 marketed drugs. He developed deep sequencing and genome partitioning algorithms (founding scientist, Celera Genomics) and several first whole genome arrays (Agilent) and partnered with pharma/biotech to integrate these novel approaches into drug development. Stuart is an inventor on several patents, authored 20 journal articles and presented at numerous global scientific and business conferences. He received a BA, High Honors at UCSC and a Ph.D. in Endocrinology at UC Berkeley, Cancer Research Lab (NCI Fellowship). He completed his post-doctoral work with Dr. JW Gray at UCSF & LBNL as a Distinguished Human Genome Postdoctoral Fellow (DOE).